

My Approach to ...
Transferring from Pharmaceutical
to Neuro-optometric
Rehabilitative Management of
Anisometropic Amblyopia

Samantha Slotnick, OD, FAAO, FCOVD
Private Practice, Scarsdale, NY
DrSlotnick@DrSlotnick.com
Website: DrSlotnick.com

Disclosures

- No Financial Interest in tools/ techniques used.

Abstract

Anisometropic amblyopia is benefiting from recent studies highlighting the **value and long-term success of "perceptual learning."**

Parents wishing to do more for their child with amblyopia have often been involved in **traditional and/or pharmaceutical management** prior to seeking rehabilitative care.

Abstract

A case is presented in which a patient was **successfully transitioned** into **rehabilitative management** while **tapering** pre-existing use of **atropine**.

Challenges in parent discussion are presented as a key factor in gaining parent confidence while changing management strategy from a pharmaceutical to a rehabilitative treatment model.


Purpose

- Demonstrate the impact of active, visually-directed engagement on visual performance.
- Demonstrate that fixation and ocular motility training are not splinter skills, but rather *foundation* skills which potentiate greater binocular performance.
- Discuss management challenges *and opportunities* when engaging a parent who has been content with the medical model, *while still upholding respect for the traditional eye care professional.*

Outline

- Entering profile
- Interim profile
- Post-therapy profile
- Therapy provided
- Conversations & Management
- Case update: Ongoing Developmental Visual Guidance

MAT...Transferring from Pharm to Rehab Mx, Amblyopia



erin

- H/o Amblyopia OD, variable E(T)
- Patching
- Atropine
- History

4.5m

- Repeatedly: Progress during Tx/ Regressions after.

Entering Profile: JB

- 5.4 yo girl
- Currently under OMD mx
- H/o Amblyopia OD, variable E(T)
- Patching age 3.10m thru 4.5m:
 - increased 3 to 8 hrs/day: unsuccessful.
- Atropine instituted at age 4.5m, daily.
 - Was using atropine QOD (directed to use QD, but became QOD due to patient's resistance).
- History of stopping/ restarting atropine Tx
 - Repeatedly: Progress during Tx/ Regressions after.

Entering Profile: JB

- Parent conference 4 days prior to exam:
 - "Had a cycloplegic refraction yesterday"
 - OMD record showed "Large LET"
 - All prior records showed small accommodative ET.
- *I requested patient switch to QOHS prior to optometric exam.*

"Is there anything to be done for rehabilitation for amblyopia?"



Parent has functional concerns...

- Bump: "Friendly" comment
- Troub we've all had:
- Very c
- Has a "Oh I bump into stuff all the time, don't worry about it."
- Gets
- Challe
- Extre skills



Mr. Bump
TEXTONPHOTO™

verbal

Parent has functional concerns...

- Bumps into things
- Trouble walking downstairs
- Very cautious
- Has a bad sense of orientation
 - Gets lost in large areas
- Challenges with drawing skills
- Extremely bright when it comes to verbal skills and auditory learning & music

MAT...Transferring from Pharm to Rehab
Mx, Amblyopia


Entering Profile: JB (age 5.6m)

	Distance	Near
OD +2.75 sph	20/40	20/32
OS +0.25 sph	20/30-	20/25
OU	20/30	20/32

Leans in/ chin down for near

- **VO Star:** hypo-projects OU; high eso; poor grasp
OU, OS < OD; **Profuse tearing**
- **Stereo:** 100" Wirt, (-) RDS
- **EOM:** Cannot fixate or follow beyond central 10°
- **Nearpoint ret:** balanced accn w/ **+4.00 OD/ +1.25 OS**
- **Added Yoked Prism:** 1^BD OU: righted posture
 - > Rxed this



> Continue Atropine 1% 1gtt OS QOHS



Interim Profile after 3 mos VT, Age 5.9m

- Assessment performed while still on atropine OOHS
 - Last dose 16 hrs earlier
- Ocular motility ↑
- Stereo: (+) weak RDS (presence/absence of shapes, but not identification)
 - **40" Wirt circles**
- Near VA... OS limited due to atropine
- Fusion: Negative BI recovery at distance

> Requested follow-up exam after 10 day atropine washout.




Interim Profile, Age 5.9m, 6.0m

- **Temper tantrums!** new emergence on D/C atropine:
More willful (and more effective at exercising will with functioning accn!)

> Monitor after 3 mos w/o atropine, **no VT** (age 6.0):


- ↑ in stereo: (+) RDS 250" and 20" Wirt.
- Closing OS to engage processing OD
- Crowding OD; BC DVA 20/30 OD
- Poor fusion at D and N, negative or no recoveries.
- AHP, tilt to right

MAT...Transferring from Pharm to Rehab
Mx, Amblyopia



- Interim Profile, Age 5.9m, 6.0m
- *Recommended additional 3 mos VT*
 - Develop Binocular recoveries
 - Develop Accn OD, OS OU
 - Develop Fixation, esp. 2[^] gaze

- Post-Therapy Profile, Age 6.4m
- Immediately post-therapy:
 - Greatest progress areas:
 - ↑ Ocular motility
 - Sustained ranges; positive recoveries D&N
 - ↓ EP thru near add
 - ↓ AHP
 - *Recommended some maintenance activities:*
 - Continue to build MAR (accn) and fixation
 - Work with Marsden Ball (real space fusion/localzn)
 - Saccadic/ Body organization
 - visual-motor-speech planning (Slap Tap Reading series)



- Therapy Provided, 1st block
- **Visually-guided motor activities** integrated with a metronome and both **saccadic** and **smooth pursuit** eye movements
 - **Fine motor control** at Near
 - **Visual biofeedback** w/ light at Distance
 - **Visual information processing skills** over a broad retinal area:
 - **Visual-spatial memory**
 - **Visual-sequential memory**

- Therapy Provided, 1st block
- **Visually-guided motor activities** integrated with a metronome and saccadic eye movements
 - **Organized** either:
 - Central-peripheral
 - Left-to-right and top-to-bottom
 - At near-point, **fine motor control** was engaged with touching or manipulating small objects with pincer grasp for visually-guided motor control and feedback for accuracy.
 - Pegs, Blocks, "Birthday Cake" rings around sticks
 - VMF series
 - At **longer distances**, feedback was supported with aiming a flashlight and observing accuracy of motor control within a visual target.
 - Central-peripheral patterns
 - 4-Corner Saccades

Therapy Provided, 1st block

- **Visual information processing skills** over a broad retinal area were presented, including:
 - **Visual-spatial memory** exercises, encouraging viewing over an area with **tachistoscopic** ("fast look") exposure;
 - **Visual-sequential memory** exercises, encouraging ability to track a moving target over a stable area and to reproduce the pattern.
- **Smooth pursuit exercises** were conducted with:
 - Peg insertion into a rotating pegboard
 - Marsden Ball smooth pursuits (Greenwald series)
 - Cognitive tasks were added to improve automaticity of eye movements without conscious control.

Therapy Provided, 2nd block

- **Accn-** MAR at D, N; Bi-ocular AR
- **Stereo-** relative depth; jump ductions
- **Marsden Ball-** looming, VMI series, bunt ball, ball/loop; smooth pursuit (Greenwald)
- **Visual-vestibular activities-** Infinity Walk; "Slotnick Scramble"
- **VMI-** bisecting; spatial planning ("line patterns" horizontal & vertical); Chalkboard Circles

Conversations & Management

- **Challenges to overcome:**
 - Mother presented to OMD that she was considering VT.
 - OMD Notes...

Conversations & Management

Considering VT-Slotnick.
Not sure what her goal is to have eval.

OMD writes in A/P:
Do not rec VT- no indication

Along with:
Large LET
Mixed amblyopia OD, improving.
Continue Atropine QOD OS
Update Rx to +3.25 / +1.00
Check in 3 mos

Conversations & Management

- Extended discussion w/ parent:
Why change atropine to HS rather than AM?
 1. Atropine enables MFBF, but *disables feeling of control* over vision
 2. Longer wear-off period: More opportunities for control by daytime (esp. 2nd day, QOHS).
 3. Active therapy is enhancing JB's control over each eye...which is more effective than simply handicapping the preferred eye!

Conversations & Management

- Interim discussion:
Some immature behavior,
"temper tantrums" once she was taken off atropine:
 - More willful (and more effective at exercising will!)...
 - *Appropriate for development!*



Conversations & Management

- **Parent fear of D/C'ing atropine...**
"Won't she need this for life?"
- Multiple occasions requiring education on
 - purpose of atropine and
 - effect of atropine on focusing control.


Conversations & Management

- Ongoing reinforcement of concept of "Developmental visual guidance"



Conversations & Management

- **Pleasant Surprise:**
 - Conversation with mom following a re-eval with JB's original OMD:
 - Doc was double checking records to see that it was the same child. "What did you do??"
- Mom tells OMD: **We did VT with Dr. Slotnick...**
- "Tell Dr. Slotnick I say, 'hi!'"




Case Update, Ongoing Developmental Visual Guidance




Post-Therapy Profile, Age 6.7m

- 3 mos post-therapy:
 - Continues to get (+)RDS stereo and 20" Wirt.
 - Regression in ocular motility performance
 - Regression in binocular recoveries at distance, near.
 - Demonstrated 2^RET at DV only.
→ Increased Rx (+) power: stabilized turn.
 - Modified Rx, increased plus at DV, maintained unequal adds
 - OD +4.75 sph /+1.25 ADD
 - OS +3.00 -0.50 x 180 /+0.75 ADD

Entering VO Star



MAT...Transferring from Pharm to Rehab Mx, Amblyopia



- ### Post-Therapy Profile, Age 6.9m
- Additional 8 weeks, following Rx update:
 - No ET at distance
 - ↑ DVA OD, ↑ NVA OD (20/16!)
 - ↑ ocular motility performance
 - Stable binocular ranges and recoveries in phoropter.
 - Improving accom amplitudes
 - Small right hyperphoria identified in phoropter only, increases on prolonged dissociation in phoropter.
 - Plan: Monitor quarterly
 - Educate mother: There may be opportunities for future VT as demands change.
- 

- ### Take Home Lessons
- Transitioning a **parent** from medical/pharmaceutical Mx of Amblyopia to Rehabilitative Mx presents challenges in *parent education*.
 - While gaining parent confidence in the effectiveness of an active VT Rehab program (esp. when OMD warns against it), it may be worth **continuing existing atropine penalization**, short term.

- ### Take Home Lessons
- **Pauses between VT blocks** give both parent and doctor the opportunity to monitor stability of vision gains.
 - **Pulsed VT blocks** also
 - help parent to appreciate objectives of treatment, and
 - builds confidence in management plan when gains are maintained.

Take Home Lessons

- Fixation accuracy and oculomotor control are foundational skills which facilitate:
 - better acuity, which in turn facilitates
 - better appreciation of accommodative control,
 - visual information processing over a retinal area (saccades), which in turn facilitates
 - better binocularity
- Fixation and oculomotor skills may be developed in the presence of atropine Tx.

Detailed exam findings presented over following slides, for reference/ review:

Age	5.6 years.mos	5.9 years.mos	5.9 years.mos
Atropine?	Atropine OS, 40 hrs ago	Atropine OS, 16 hrs ago	no atropine x 10 days
VT?		post 12 sessions VT	post 12 sessions VT
Wearing Rx OD	+2.75 sph	+4.00 sph = 1*BD	+4.00 sph = 1*BD
OS	+0.25 sph	+1.25 sph = 1*BD	+1.25 sph = 1*BD
DVA			
OD	20/50, 40	20/50, 30 ²	20/40, 30 ²
OS	20/40, 30-	20/40, 30+	20/30, 25 ²
OU	20/30, --	20/40, 25	20/30, 25 ²
NVA			
OD	20/32, 25	20/20	20/50, 20
OS	20/25	20/32	20/25+
OU	20/32, 25	20/25	20/25, -, 16
Cover Testing			
Dist	UCT: Φ ACT: 6-8 EP	4*EP	UCT:4*RET ACT: 6*eso
Near	UCT: Φ ^o ACT: 8*EP ^o	6-12" EP ^o w/ inc attn recovers quickly	Φ ^o
RDS stereo		Entering: (+) absence/ presence depth	(-); at end, c +5.50+3.00
Wirt stereo	(-) 100"	After eval, with +1.75 OS: (+)500"	(+) 250"RDS 70"; repeat c TF: 40" At end of exam, thru TF: +5.50 OD/ +3.00 OS:

	6.0 years.mos	6.4 years.mos	6.7 years.mos	6.9 years.mos
no atropine	no atropine	no atropine	no atropine	no atropine
after new Rx/ pause VT	after 12 sessions VT	after 12 sessions VT	Assess stability/ no VT	after new Rx, no VT
Unequal ADDS:	Unequal ADDS:	Unequal ADDS:	Unequal ADDS:	Unequal ADDS:
+4.25 sph/ +1.25	+4.25 sph/ +1.25	+4.25 sph/ +1.25	+4.25 sph/ +1.25	+4.75 sph/ +1.25
+2.25 sph/ +0.75	+2.25 sph/ +0.75	+2.25 sph/ +0.75	+2.25 sph/ +0.75	+3.00-0.50x160/ +0.75
20/50, 40 ² crowd WL:40"	20/40, 30 ²	20/50, 30 ¹⁺²	20/40, 25 ³	20/40, 25 ³
20/25 ² , 20 ³	20/25 ¹⁺²	20/25 ² , 20 ²	20/25 ² , 20 ³	20/25 ² , 20 ³
25, --	30, 25 ²⁺²	20/20,	20/25, 20 ²	20/25, 20 ²
20/32, -, 20	20/40, 25	20/32, +	20/20, 16	20/20, 16
20/25, -16	20/20, +	20/25, -16	20/25, 20	20/25, 20
20/25, -16	20/50, 25, 16	20/32, -, 20	20/25	20/25
	UCT:2*RE(T)	UCT:2*RET	UCT: Φ	
	ACT: 3-4*eso	ACT: 4*eso	2-3*EP	
Φ	DV: 6-8*EP ^o	UCT: Φ ^o	UCT: Φ ^o	
4-6*EP ^o	ADD: 3-4*EP	ACT: 6-+4*EP ^o	4*EP ^o	
(+)250"	(+)250"	(+)250"	(+)250"	
70", 20"	100", 40", 20"	70", 30", 20"	50", 20"	
4 - 3+ - 4+	5 - 5 - 4	3 - 2+ - 3+	5 - 3 - 4+	

Age	5.6 years.mos	5.9 years.mos	5.9 years.mos
Wirt stereo	100"	140", 40"	70"; repeat c TF: 40" At end of exam, thru TF: +5.50 OD/ +3.00 OS:
NSUCO Pursuits	1 - 1+ - 2	3 - 2 - 4	4 - 3 - 4+
NSUCO Saccades	1 - 1+ - 1	4 - 4+ - 2+, eyes, then head	2+ 3 - 4
Woff Wand Rotations	~1+	3+, 10 sec fixation	~3+
WW Fixations	~1, OS tropes LET at near	3+	~3+
	Cannot sustain a fixation Can't hold NIF fixation Poor inhibition	trouble c release/ divergence	difficulty c inhib
Retinoscopy OD	+4.75 sph	+5.00 sph	+5.25 sph
OS	+1.50 sph	+3.25 -0.75 x 180	+3.50 sph
Subjective, c VA OD	+4.75 sph 20/60, 50 ²	+5.00 -0.50 x 090, 20/25 ³	+4.25 sph, 20/25+
OS	+1.75 sph 20/30-, 25 ³	+3.00 -0.50 x 180, 20/25 ¹⁺	+2.50 sph, 20/20 ³
Binoc Balance OD			
OD	+4.50 sph	+4.25 sph	
OS	+2.25 sph ; 20/20 ³	+2.50 sph, 20/25 ³	
		(drops eye)	

	6.0 years.mos	6.4 years.mos	6.7 years.mos	6.9 years.mos
(+)250"	(+)250"	(+)250"	(+)250"	
70", 20"	100", 40", 20"	70", 30", 20"	50", 20"	
4 - 3+ - 4+	5 - 5 - 4	3 - 2+ - 3+	5 - 3 - 4+	
4 - 2+ - 4+	5 - 4+ - 5	3 - 2+ - 3	5 - 4 - 4+	
4	5	3+4	4+	
4+	5-	3+	4	
		Rotations degrade on obliques, increased fixation loss.	Rotns: jaw engages	
		Fixations- oriented, good inhibition;	Fixns: trouble with inhibition: early divergence.	
saccades:	blinks betn NIF at times	weak stability of fixation >2sec.		
occ1 pause at midline				
+5.50-0.25x160	+5.50 sph	+5.75-0.25x005	+5.75-0.75x175	
+2.75 sph	+3.50-0.50x160	+4.00-0.50x160	+3.50-0.75x175	
+4.50sph, closing OS, 20/30	+4.75, 20/30-	+5.00sph, 20/30 ²	+5.00 sph, 20/25 ^{2(WL)}	
+2.50sph, 20/25-, 20 ³	+2.75-0.50x160, 20/20 ³	+3.00-0.75x145, 20/20 ²	+3.00-0.75x180, 20/20 ²	
+4.50 sph	+5.00 sph	+4.75sph	+4.75sph	
+2.25 sph, 20/25, 20 ²	+2.50-0.50x160, 20/20 ²	+3.00-0.50x145, 20/20 ²	+3.00-0.50x180, 20/20 ²	

MAT...Transferring from Pharm to Rehab Mx, Amblyopia

Age	5.6 years.mos	5.9 years.mos	5.9 years.mos
Distance: VG phoria			2 exo, 2°BU OS; LI 6/3 (BU) LS 2/0 (BD)
BO		1 exo, 2°BU OS	BO x / ~40 / 4
BI		BO x / 19 / 4 BI x / 7 / -4	BI x / 18 / 0 (delayed reports, OD suppressing)
Near: VG phoria			2 exo, 0
BO		BO x / 19 / 4	BO x / 20 / 4
BI		BI x / 7 / -4	BI x / 26 / 6
Additional assessments	MEM: OD+4.00 ~+0.50 lag OS+1.75: leads +4.00 +1.25 ~ balances engagemnt stabilizes gait; NVA: 20/25 OU DVA: 20/50, 25 ² OU		FCC +0.50(V) UFCC +5.75 sph +2.25 sph MEM c TF: +4.50 ~+1.00 lag +2.75~+0.50 lag Engages, comfort c: OD +5.50 OS +3.00 "subtract" -0.75 OU, pref to "-1.00" for DV TF DV: + 4.75 OD +2.25 OS: 1-2°RET, 4°eso

	6.0 years.mos	6.4 years.mos	6.7 years.mos	6.9 years.mos
	12 eso, 2°BU OS		3 eso, 2°BUOS	4 eso, 1.5°BU->3°BU OS
BO x / 24 / NR		PB	BO x / 27 / 2	
BI (NR) / -12(BO)		BO x / 25 / 16 BI x / 14 / 10	BI x / 36 (late report) / 1 "I focused on the not real one"	BO x / 32 / 14 BI x / 12 / 3
	3 exo		10 eso, 1.5°BUOS	2 eso, 0
BO x / 40 / NR		PB	BO x / 40 / 25	BO x / 24 / 15
BI x / 20 / -12		BO x / 16 / 1	BI x / 35 / 5	BI x / 11 / 5
Additional assessments		free space: TF +5.00 sph +2.50-0.50x160 accepts -0.50 OD; -0.75 OD decreases VA OU cyl x160~x180 OS. MEM, best symmetry +0.75 OU	TF: DV Balance: accepts - 0.50 DC x 180, 20/20 ¹ Improved OD fixation, Dist CT: 0 MEM: tried +0.75 OU over bal: reads, slightly dim reflex OD. Changed to +1.25 OD/ +0.75 OS: brighter reflex, engaged with low lag, increased fluency; Easy 20" stereo on Wirt.	UFCC over balance: OD +1.25 OS +0.75(V) Repeat FCC with above: Takes OD +1.50(H) OS +1.00(H)

Additional assessments	MEM: OD+4.00 ~+0.50 lag OS+1.75: leads +4.00 +1.25 ~ balances engagemnt accepts 1°BD OU, stabilizes gait; NVA: 20/25 OU DVA: 20/50, 25 ² OU		FCC +0.50(V) UFCC +5.75 sph +2.25 sph MEM c TF: +4.50 ~+1.00 lag +2.75~+0.50 lag Engages, comfort c: OD +5.50 OS +3.00 "subtract" -0.75 OU, pref to "-1.00" for DV TF DV: + 4.75 OD +2.25 OS: 1-2°RET, 4°eso Pref +4.25 OD +2.25 OS @DV, 20/25 ²
Age	5.6 years.mos	5.9 years.mos	5.9 years.mos
Rx given			Unequal ADDS: OD +4.25 sph/ +1.25 OS +2.25 sph/ +0.75 RTC 3 mos, no VT

Additional assessments	free space: TF +5.00 sph +2.50-0.50x160 accepts -0.50 OD; -0.75 OD decreases VA OU cyl x160~x180 OS. MEM, best symmetry +0.75 OU	TF: DV Balance: accepts - 0.50 DC x 180, 20/20 ¹ Improved OD fixation, Dist CT: 0 MEM: tried +0.75 OU over bal: reads, slightly dim reflex OD. Changed to +1.25 OD/ +0.75 OS: brighter reflex, engaged with low lag, increased fluency; Easy 20" stereo on Wirt.	UFCC over balance: OD +1.25 OS +0.75(V) Repeat FCC with above: Takes OD +1.50(H) OS +1.00(H)	
Age	6.0 years.mos	6.4 years.mos	6.7 years.mos	6.9 years.mos
Resume VT, develop accn and binoc, and fixation across midline		consider cyl OS, consider +0.75 OU RTC 3 mos	Update Rx to stabilize Dist ET: Unequal ADDS: OD +4.75 sph/ +1.25 OS +3.00-0.50x180/ +0.75	continue with Rx RTC: Monitor Qtrly, guide visual development

References

- Levi DM, Knill DC, Bavelier D. Stereopsis and amblyopia: a mini-review. Vision research. 2015 Sep 1;114:17-30.
- Levi DM, Li RW. Perceptual learning as a potential treatment for amblyopia: a mini-review. Vision research. 2009 Oct 29;49(21):2535-49.
- Ho CS, Giaschi DE. Stereopsis-dependent deficits in maximum motion displacement in strabismic and anisometropic amblyopia. Vision research. 2007 Sep 1;47(21):2778-85.
- Polat U, Ma-Naim T, Spierer A. Treatment of children with amblyopia by perceptual learning. Vision research. 2009 Oct 29;49(21):2599-603.
- Zhou Y, Huang C, Xu P, Tao L, Qiu Z, Li X, Lu ZL. Perceptual learning improves contrast sensitivity and visual acuity in adults with anisometropic amblyopia. Vision research. 2006 Mar 1;46(5):739-50.

Discussion welcome!

Samantha Slotnick, OD, FAO, FCOVD
 DrSlotnick@DrSlotnick.com
 www.DrSlotnick.com